News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Myelin Repair Foundation And National Institutes of Health (NIH) Enter Agreement For The Clinical Development Of MRF-008, A Drug Repurposing Opportunity For Multiple Sclerosis



1/27/2014 10:02:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SARATOGA, Calif.--(BUSINESS WIRE)--The Myelin Repair Foundation (MRF) today announced it has entered a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) to assess MRF-008, as a potential therapeutic for multiple sclerosis (MS). This CRADA will facilitate collaboration between the MRF and National Institute of Neurological Disorders and Stroke (NINDS) at the NIH Clinical Center to study MRF-008, a drug identified by the MRF as a potential neuroprotective therapeutic to enhance repair in multiple sclerosis patients.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES